Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid tumors that are not amenable for treatment with curative intent as follows:~  1. Metastatic pancreatic ductal adenocarcinoma; or~ 2. Phase 2 only: Stage IIIb/IV NSCLC or other advanced solid tumors with documented positive KRAS or NRAS mutation as determined using a validated test performed in a CAP/CLIA-certified laboratory (or other comparable local or regional certification).~* Have had disease progression during or following at least 1 and not more than 2 prior lines of treatment for advanced or metastatic disease.~* Patients with NSCLC must have previously received treatment with an anti-PD-1 or anti-PD-L1 agent for advanced disease.~* Measurable disease as per RECIST v1.1 criteria.~* Provision of a baseline tumor sample.~* Age ≥18 years (Japanese patients must be ≥20 years old)~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.~* Adequate bone marrow, renal and liver functions.~* Adequate cardiac function.~* Informed consent provided.~Exclusion Criteria:~* Prior treatment with avelumab, a PARP inhibitor or MEK inhibitor.~* Prior systemic anti-cancer therapy within 2 weeks prior to study enrollment.~* Persisting toxicity related to prior therapy.~* Current use of immunosuppressive medication.~* Known history of immune-mediated colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis, uveitis or iritis.~* Active or prior autoimmune disease that might deteriorate when receiving an immunostimulatory agent.~* Diagnosis of myelodysplastic syndrome (MDS).~* Known symptomatic brain metastases requiring steroids.~* Known history of testing positive for HIV or hepatitis.~* Clinically significant (ie, active) cardiovascular disease.~* History of thromboembolic or cerebrovascular events.~* Current or anticipated use of a P-gp inhibitor, inducer, or inhibitor of breast cancer resistance protein (BCRP)~* Uncontrolled hypertension.~* Concurrent neuromuscular disorder that is associated with the potential of elevated creatinine kinase.~* Known history of Gilbert's syndrome.~* History or current evidence of retinal degenerative disease, retinal vein occlusion (RVO) or current risk factors for RVO.~* Other acute or chronic medical or psychiatric condition.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Avelumab and binimetinib (Type: EXPERIMENTAL): Open label
- Avelumab, binimetinib and talazoparib (Type: EXPERIMENTAL): Open label
- Binimetinib and talazoparib. (Type: EXPERIMENTAL): Open label.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility